Specialty Oncology
-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
-
Considerations in Selecting Patients for Trimodal Therapy for Muscle-invasive Bladder Cancer
Adam S. Feldman, MD, MPH, and colleagues review the patient-related and tumor-related factors that should most strongly influence the decision between trimodal therapy and radical cystectomy for patients with muscle-invasive bladder cancer.
-
Pembrolizumab and Nivolumab Not Linked to Increased Mortality in Cancer Patients with Interstitial Lung Disease
Although a thorough risk–benefit analysis is necessary, PD-1 inhibitors should not be uniformly withheld from cancer patients who have underlying interstitial lung disease, according to a study by Sydney B. Montesi, MD, and Amita Sharma, MBBS, clinician-researchers at Massachusetts General Hospital, and colleagues.
-
Palliative Care Benefits Patients Undergoing Stem Cell Transplantation
Massachusetts General Hospital researchers have found that even apart from medication for symptom control, palliative care has benefits for patients facing the prolonged hospitalization required for hemopoietic stem cell transplantation.
-
Size of Largest Colorectal Liver Metastasis is an Independent Prognostic Factor After Neoadjuvant Therapy
In patients with colorectal cancer metastasis confined to the liver, Motaz Qadan, MD, PhD, of the Department of Surgery, found that larger metastases predict poorer disease-free and disease-specific survival after neoadjuvant chemotherapy and liver resection.
-
Limb-Salvage Surgery for Upper-Extremity Sarcoma Has Long-term Advantages Over Amputation
In a retrospective study of patients with upper-extremity sarcoma with prospective follow-up, researchers and surgeons at Massachusetts General Hospital found that, although the reoperation rate was higher, limb salvage with complex reconstruction had long-lasting functional advantages over amputation.
Mass General Cancer Center
-
Andrew T. Chan, MD, MPH
Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
Prior Antibiotics Linked to Increased Risk of New Diverticulitis in Older Adults
-
David M. Langenau, PhD
Associate Professor of Pathology, Harvard Medical School, Associate Chair for Research, Department of Pathology, Massachusetts General Hospital
-
J. Keith Joung, MD, PhD
Professor of Pathology, Harvard Medical School, Center for Cancer Research, Desmond and Ann Heathwood MGH Research Scholar
Recent Article
CRISPR Base Editors Can Induce Wide-Ranging Off-Target Edits in RNA
-
Joseph H. Schwab, MD
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopedic Surgery, Harvard Medical School
Recent Article
Osteoporosis Is Underrecognized, Undertreated Among Adults with Spinal Deformity Undergoing Long Fusion
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
Medical Grand Rounds: Advancing New Therapies for COVID-19: Antiviral, Immunomodulation and Beyond
-
Marcela G. del Carmen, MD
Chief Medical Officer, Massachusetts General Physicians Organization, Gynecologic Oncologist, Center for Gynecologic Oncology
Recent Article
How Research Has Impacted Care for Cervical Cancer video
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma -
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Mass General Researchers Find Link Between Protein Signature and Severe Health Decline in COVID-19 Patients
-
Raul Mostoslavsky, MD, PhD
Laurel Schwartz Professor of Medicine in the Field of Oncology, Mass General Cancer Center, Center for Cancer Research
Recent Article
Inactivating Mutation in the Histone Deacetylase SIRT6 Discovered to Be a Cause of Fetal Demise
-
Whitfield B. Growdon, MD
Center for Gynecologic Oncology
Recent Article
Understanding the Molecular Underpinnings of Gynecologic Cancers
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Immunotherapies to Treat Glioblastoma
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
